Overview
Setting Goals and Expectations With CGRPs for Migraine Prevention
New Horizons in Migraine Prevention: Pathways to Personalized Care with CGRPs—the Year in Review
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Join an expert faculty panel as they discuss incorporating anti-CGRP monoclonal antibodies into daily clinical practice for migraine prevention. This video-based session will integrate didactic presentation, a case-based panel discussion, and expert review of clinical evidence, guideline recommendations, special considerations, and real-world use.
This activity is intended for neurologists, headache specialists, pain specialists, NPs, PAs, and other HCPs who treat patients with migraine disorder.
Migraines represent a common, debilitating disorder that continues to be both undertreated and underdiagnosed. Ninety-five percent of chronic migraine patients do not receive appropriate diagnosis or care, and the few that do, suffer from poor long-term treatment adherence. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are an emerging preventative migraine therapy class that offer benefits over traditional systemic prophylaxis. This activity will review best practices for incorporating CGRP mAbs into daily clinical practice.
Upon completion of this activity, participants will be able to:
• Develop effective strategies for incorporating CGRP mABs into daily clinical practice
• Formulate comprehensive management plans for migraine patients on preventative treatment
• Review current treatment guidelines and patient eligibility for use of CGRP mABs
• Develop effective strategies for incorporating CGRP mABs into daily clinical practice
• Formulate comprehensive management plans for migraine patients on preventative treatment
• Review current treatment guidelines and patient eligibility for use of CGRP mABs
This activity is sponsored by The Academy for Continued Healthcare Learning.
This activity is supported by an educational grant from Lundbeck.
Jessica Ailani, MD, FAHS, FAAN
Professor, Neurology
Director, Headache Center
Medstar Georgetown University Hospital
Washington, DC
David W. Dodick, MD
Professor of Neurology, Department of Neurology
Mayo Clinic College of Medicine
Consultant in Neurology and Program Director, Mayo Clinic Neurology Residency Program
Director, Headache, Sports Neurology, and Concussion Programs
Mayo Clinic
Scottsdale, AZ
Lawrence C. Newman, MD, FAHS, FAAN
Professor, Neurology
NYU Grossman School of Medicine
Director, Headache Division
NYU Langone Health
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Jessica Ailani, MD, FAHS, FAAN
Consulting Agreements: Alder, Amgen, Allergan, Biohaven, Eli Lilly and Company, Impel, Neurodiem, Revance, Satsuma, Theranica, Teva, Zosano
Speakers’ Bureau: Allergan, Amgen, Biohaven, Eli Lilly and Company, Teva
David W. Dodick, MD
Board of Directors: Epien Medical
Consulting Agreements: Allergan, Amgen, Biohaven Pharmaceuticals, Cerecin, Clexio Biosciences Ltd., Ctrl M Health, Eli Lilly, eNeura, Equinox Pharma, Linpharma, Lundbeck, Novartis, Impel Neuro Pharma, Nocira, Pieris Pharmaceuticals, Inc., Promius Pharma, LLC, Revance, Satsuma Pharmaceuticals, Theranica, WL Gore, XoC Pharmaceuticals, Zosano Pharma, Upjohn (Division of Pfizer)
Patent 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis
Stock Options: Ctrl M Health, Epien Medical, Healint, Nocira, Theranica
Lawrence C. Newman, MD, FAHS, FAAN
Advisory Board: Allergan, Amgen, Lilly, Supernus, Theranica
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.
Completion of this activity including the pre, post, and follow-up assessments qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
